Levemir Insulin Shortage Crisis Threatening Millions With Type 1 Diabetes Treatment Options

About This Blog

In this episode of Fountain of Vitality with LaMont Leavitt, Alison Smart represents over one million Americans facing a healthcare crisis most people don't know exists. As President of Insulin Choice, Smart transformed personal tragedy into national advocacy after her 13-year-old daughter's type 1 diabetes diagnosis revealed the fragility of insulin supply chains and the dangerous misconception that all insulin formulations are interchangeable. The removal of Levemir insulin, known generically as insulin detemir, from the US market in December 2023 represents more than a single product discontinuation. It signals a broader consolidation trend where manufacturers prioritize lucrative weight loss medications over essential diabetes treatments, leaving vulnerable populations including pregnant women, teenagers, and athletes without proven therapeutic options.

The Thanksgiving Diagnosis That Changed Everything  

Alison Smart's introduction to type 1 diabetes came unexpectedly during Thanksgiving weekend 2021. Her 18-year-old daughter recognized warning signs during a restaurant meal, having learned about diabetes through a school project. She noticed her younger sister's excessive water drinking and frequent bathroom trips. Looking back, Smart identified symptoms that seemed innocuous: leg cramps during tennis matches, weight loss, and fatigue that she attributed to normal adolescent growth spurts rather than metabolic crisis.

The initial diagnosis led to standard treatment prescribing Lantus, insulin glargine, the most commonly used long-acting insulin. The prescribing physician casually mentioned that several options existed and recommended contacting the insurance company to determine which formulation they preferred covering. This approach revealed a systemic problem Smart would later challenge: the widespread medical assumption that basal insulins are functionally interchangeable despite significant pharmacological differences.

Why Insulin Detemir Matters After Twenty Years  

Insulin detemir served patients reliably for 20 years before Novo Nordisk removed it from the US market. This formulation offers distinct advantages that make it irreplaceable for specific patient populations. One injection lasts approximately 8 to 14 hours, while insulin glargine remains active for 20 hours. This shorter duration enables flexible split-dosing essential for patients whose insulin needs fluctuate dramatically: teenagers experiencing hormonal surges, women navigating menstrual cycles, pregnant women facing rapidly changing requirements, and athletes managing exercise-induced blood sugar swings.

Insulin detemir represents the only basal insulin that clinicians can dilute, critical for pediatric patients requiring tiny doses. Parents administering insulin to young children must estimate half-unit doses that resemble drops within syringes. Dilution capability allows precise measurement, reducing dangerous hypoglycemic episodes. Clinical advantages extend beyond dosing flexibility. Insulin detemir demonstrates lower hypoglycemia risk compared to insulin glargine, causes less weight gain, and is not acidic, meaning it doesn't cause the injection site burning pain that glargine's acidic formulation creates for daily injections.

The Pregnancy Safety Evidence That Physicians Trust  

Pregnancy represents one of the most compelling use cases for maintaining insulin detemir availability. The formulation has been the subject of randomized controlled trials demonstrating safety and efficacy during pregnancy, evidence giving obstetricians and endocrinologists confidence when treating diabetic mothers. This research base does not exist for insulin glargine. Insulin requirements during pregnancy change drastically as fetal development progresses and especially during delivery. The shorter acting profile allows rapid adjustment to these fluctuating needs, enabling tighter blood glucose control that directly impacts pregnancy outcomes.

Since Levemir became unavailable, physicians specializing in diabetes and pregnancy report increased difficulties managing patients. As Smart pointedly asks, who would fund research deliberately using inferior insulin during pregnancy to document increased NICU admissions, early deliveries, or adverse birth outcomes? Women with gestational diabetes face particular challenges since their temporary condition requires insulin management only during pregnancy. These patients typically do not use insulin pumps, making the loss of the safest, most proven option especially problematic.

The Athlete and Teenager Challenge  

Smart's daughter exemplifies why insulin detemir matters for young, active patients. During the first four months using insulin glargine, her daughter experienced wide blood glucose swings disrupting tennis playing and daily life. Switching to insulin detemir proved transformative through twice-daily dosing matching insulin delivery to changing needs. Tennis tournaments present unique challenges because matches vary unpredictably. A player might face one 30-minute match or four three-hour matches daily.

The family tried an insulin pump the following year. It worked well during weekdays but failed during weekend tournament competition when activity became unpredictable. They returned to Levemir injection therapy, providing superior glucose stability. Teenage years compound diabetes management through growth hormone surges and menstrual cycle variations, causing insulin requirements to fluctuate dramatically. Smart's daughter experiences completely different insulin needs at various menstrual cycle points, variations that shorter-acting insulin detemir accommodates through flexible dosing adjustments.

The Weight Loss Drug Profit Motive  

Three manufacturers have dominated global insulin production for decades: Novo Nordisk, Eli Lilly, and Sanofi. Two now produce blockbuster weight loss medications including Ozempic, Wegovy, Saxenda, and Mounjaro. These GLP-1 receptor agonists generate substantially higher profit margins than insulin, shifting corporate focus toward metabolic disease treatments. Novo Nordisk manufactures 52% of the world's insulin supply yet publicly describes itself as consolidating its global insulin portfolio, signaling strategic retreat from comprehensive diabetes treatment.

The Senate HELP Committee held hearings in 2023 examining Ozempic and Wegovy pricing, bringing then-CEO Lars Jorgensen before Congress. While the hearing focused on weight loss drugs, senators raised the Levemir discontinuation issue directly. Jorgensen responded that if any company or government entity wanted to manufacture insulin detemir, Novo Nordisk would cooperate. This statement provides a potential pathway forward through licensing agreements, manufacturing partnerships, or complete FDA approval transfers.

Barriers in the Current Regulatory System  

A manufacturer in Utah contacted Insulin Choice explaining they had reverse-engineered insulin detemir, conducted successful animal studies demonstrating bioequivalence, and possessed technical capacity to produce the medication. However, current FDA requirements demand manufacturers reach 1,000-liter production capacity before applying for biosimilar approval. Building this infrastructure requires tens of millions of dollars without guarantee of regulatory approval. The approval process involves additional costs and typically extends six to eight years.

Insulin Choice filed a citizen petition with the FDA in April 2024 requesting designation of insulin detemir as a drug in shortage. This classification would trigger working with manufacturers on increasing supply, communicating with stakeholders about the shortage, and employing creative solutions for importing approved formulations from international markets. The FDA has 180 days to respond, with the deadline falling on October 12, 2024. The petition draws parallels to the FDA's 2024 response to a penicillin shortage, where regulators recognized that specific infections require penicillin treatment despite numerous alternative antibiotics.

Historical Context and OTC Classification Potential  

Insulin did not require a prescription until 1996, a relatively recent regulatory change. Regular insulin and NPH insulin remain available over the counter at pharmacies including Walmart, providing emergency access for patients who cannot afford prescriptions or lack insurance coverage. This precedent suggests OTC classification for insulin detemir could expand access while maintaining safety.

Several factors support OTC status. The medication has 20 years of established safety data demonstrating a lower hypoglycemia risk compared to alternatives. Patients with type 1 diabetes already self-manage through blood glucose monitoring, carbohydrate counting, and insulin dose calculations. OTC classification would support competitive pricing by eliminating insurance company formulary control determining which insulins patients access based on reimbursement negotiations rather than clinical appropriateness. Additionally, OTC status creates multiple supply pathway options allowing direct patient purchasing and alternative distribution channels.

The Three Pathways Forward  

Insulin Choice advocates for three specific policy actions that could restore insulin detemir availability. First, the FDA should officially declare insulin detemir a drug in shortage, carrying specific regulatory implications including expedited biosimilar approval pathways, active FDA communication with potential manufacturers, and authorization to import FDA-approved formulations from international markets where Levemir remains available.

Second, Congress should reallocate Special Diabetes Program funds to support insulin manufacturing, particularly for formulations at risk of market removal. The Special Diabetes Program provides federal funding for diabetes research and treatment access. Redirecting a portion toward maintaining essential insulin availability would address immediate patient needs while encouraging domestic manufacturing capacity.

Third, the FDA should consider OTC classification for insulin detemir, expanding access and affordability while reducing barriers requiring insurance approval and prescription oversight. OTC status would allow competitive market forces to operate more freely, potentially attracting manufacturers who currently view the prescription insulin market as too heavily controlled by insurance formularies to reward clinical superiority with market share.

Taking Action to Prevent a Healthcare Crisis  

The October 12, 2024 FDA response deadline for the citizen petition represents a critical moment where public attention could influence regulatory decisions determining whether millions lose access to their only effective diabetes treatment. Healthcare organizations can help by passing resolutions supporting FDA action. The Utah Medical Association voted overwhelmingly in favor of asking the FDA to view insulin detemir as a drug in shortage, providing a model for other medical associations.

Patients and families can share their stories publicly and contact congressional representatives requesting Special Diabetes Program funding reallocation and FDA engagement. Investors and philanthropists could provide funding enabling the waiting manufacturer to meet FDA requirements and bring insulin detemir to market. The insights shared on Fountain of Vitality demonstrate that healthcare access depends on regulatory frameworks, market dynamics, and advocacy efforts ensuring patient needs influence policy decisions.

Visit Fountain of Vitality and Insulin Choice for more information about supporting insulin access advocacy and preventing future medication shortage crises affecting families managing chronic disease.

Follow the Fountain of Vitality podcast:

Website: FountainofVitality.com | Tiktok: @FountainofVitalitypod |
YouTube: @FountainofVitalityshow | Tumblr: @FountainofVitality
Facebook: FountainofVitalityShow | Rumble: Fountain_of_Vitality |
Instagram: @FountainofVitalitypodcast | Email: info@FountainofVitality.com

Follow LaMont Leavitt:

LinkedIn: @LaMontJLeavitt/ | Twitter/X: @ljleavitt1 |
InnoviHealth Website: innoviHealth.com

Follow Alison Smart, President, Insulin Choice:

LinkedIn - @Alison-Smart | Website: - AlliancetoProtectInsulinChoice.org |
Email - InsulinChoice@gmail.com